Organovo expects to meet requirements for continued listing on Nasdaq
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2025
0mins
Financial Performance: Organovo reported a preliminary cash balance of approximately $11.3 million for the fiscal year ending March 31, 2025, with net cash utilization in the fourth quarter estimated at $2M - $2.2M. The company anticipates releasing full financial results between June 9-13, 2025.
Stock Market Compliance: The company's common stock has consistently traded above the $1.00 minimum bid price since March 21, 2025, which positions it to meet Nasdaq listing requirements, pending confirmation. Additionally, Organovo expects to receive a $5M milestone payment related to a Phase 2 clinical trial for an FXR agonist within the next year.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
